Description
Anti-Rubella Virus Antibody, Non-Fucosylated (BioBet-1253ZP) is a human monoclonal IgG antibody against Rubella Virus. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Rubella Virus Infection
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Rubella Virus antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
RuV
Full Name
Rubella Virus
Background
Rubella virus (RuV) is the pathogenic agent of the disease rubella, and is the cause of congenital rubella syndrome when infection occurs during the first weeks of pregnancy. Rubella virus is the only member of the genus Rubivirus and belongs to the family of Togaviridae, whose members commonly have a genome of single-stranded RNA of positive polarity which is enclosed by an icosahedral capsid.
Alternative Names
Rubella Virus; RuV
Cellular Localization
Nucleus
Involvement in Disease
Diseases associated with RUVBL1 include Retinitis Pigmentosa 50 and Hemangioma Of Spleen.
Related Pathways
Its related pathways are Chromatin organization and Signaling by GPCR.
Function
It has single-stranded DNA-stimulated atp enzyme and atp-dependent DNA helicase (3'to 5') activity; hexamerization is considered to be the key to ATP hydrolysis, and adjacent subunits in the ring structure help ATPase active. The component of NuA4 histone acetyltransferase complex mainly participates in the transcriptional activation of selected genes through the acetylation of nuclear chromosome histones H4 and H2A. This modification may change the nucleosome-DNA interaction and promote the interaction of modified histones with other proteins that positively regulate transcription. The complex may be used to activate transcription programs related to oncogene and proto-oncogene-mediated growth induction, tumor suppressor gene-mediated growth arrest, replication senescence, apoptosis, and DNA repair. The activity of the atp enzyme and helicase of the NuA4 complex seems to be at least partially contributed by the association of RUVBL1 and RUVBL2 with EP400. When recruited to DNA damage sites, NuA4 may also play a direct role in DNA repair. Part of swr1-like complex that specifically mediates the removal of histone H2A. Z/H2AZ1 in the nucleosome. The proposed chromatin remodels the core component of the INO80 complex, which exhibits DNA and nucleosome-activated ATP enzyme activity, and catalyzes ATP-dependent nucleosome sliding. It plays an important role in the oncogenic transformation of MYC and regulates the transcriptional activation of the LEF1/TCF1-CTNNB1 complex. Cell proliferation is essential. It may bind plasminogen on the cell surface to enhance plasminogen activation.
Post-translational modifications
1.Ubiquitination at Lys22, Lys171, and Lys400 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
e137
Description
The novel antibody sequences that bind and neutralize Rubella Virus (RuV) can be used for the medical management of RuV infection, in particular for detecting the virus or for preparing pharmaceutical compositions.
Antibody Indication
Rubella Virus Infection
